Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
| SparkCures ID | 99 |
|---|---|
| Developed By | Bristol Myers Squibb |
| Generic Name | Nivolumab |
| Additional Names | BMS-936558 |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.
SparkCures is working closely with Bristol Myers Squibb to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners